BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 36876363)

  • 21. Outcomes of multicystic peritoneal mesothelioma treatment with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Zahid A; Clarke L; Carr N; Chandrakumaran K; Tzivanakis A; Dayal S; Mohamed F; Cecil T; Moran BJ
    BJS Open; 2021 Mar; 5(2):. PubMed ID: 33688945
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei of appendiceal origin: result of a single centre study.
    Di Leo A; Corvasce A; Weindelmayer J; Mason EJ; Casella F; de Manzoni G
    Updates Surg; 2020 Dec; 72(4):1207-1212. PubMed ID: 32410159
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Establishment of a Bayesian network model to predict the survival of malignant peritoneal mesothelioma patients after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy.
    Su YD; Zhao X; Ma R; Fu YB; Yang ZR; Wu HL; Yu Y; Yang R; Liang XL; Du XM; Chen Y; Li Y
    Int J Hyperthermia; 2023; 40(1):2223374. PubMed ID: 37348853
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience.
    Yan TD; Deraco M; Baratti D; Kusamura S; Elias D; Glehen O; Gilly FN; Levine EA; Shen P; Mohamed F; Moran BJ; Morris DL; Chua TC; Piso P; Sugarbaker PH
    J Clin Oncol; 2009 Dec; 27(36):6237-42. PubMed ID: 19917862
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-Term Survival in Patients Treated with Cytoreduction and Heated Intraperitoneal Chemotherapy for Peritoneal Mesothelioma at a Single High-Volume Center.
    Valenzuela CD; Solsky IB; Erali RA; Forsythe SD; Mangieri CW; Mainali BB; Russell G; Perry KC; Votanopoulos KI; Shen P; Levine EA
    Ann Surg Oncol; 2023 May; 30(5):2666-2675. PubMed ID: 36754945
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation and management of toxicity of cytoreductive surgery/hyperthermic intraperitoneal chemotherapy: the initial experience of a single centre study.
    Lemstrova R; Flasarova D; Spisarova M; Melichar B; Lovecek M; Havlik R; Neoral C; Mohelnikova-Duchonova B; Klos D
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2020 Sep; 164(3):300-306. PubMed ID: 31435073
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treating peritoneal mesothelioma with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. A case series and review of the literature.
    Stamou K; Tsamis D; Pallas N; Samanta E; Courcoutsakis N; Prassopoulos P; Tentes AA
    Int J Hyperthermia; 2015; 31(8):850-6. PubMed ID: 26382910
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study.
    Brigand C; Monneuse O; Mohamed F; Sayag-Beaujard AC; Isaac S; Gilly FN; Glehen O
    Ann Surg Oncol; 2006 Mar; 13(3):405-12. PubMed ID: 16485159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal carcinomatosis: a systematic review including evidence from Japan.
    Kitai T
    Surg Today; 2021 Jul; 51(7):1085-1098. PubMed ID: 33185798
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A case report of hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) for malignant peritoneal mesothelioma.
    Liu H; Yuan C; Huang Y; Xu N
    Asian J Surg; 2023 Dec; 46(12):5747-5748. PubMed ID: 37652775
    [No Abstract]   [Full Text] [Related]  

  • 31. A comprehensive review of childbearing after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Papageorgiou D; Manatakis DK; Papakonstantinou K; Kyriazanos ID
    Arch Gynecol Obstet; 2020 Oct; 302(4):793-799. PubMed ID: 32653946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin in pediatric patients with peritoneal mesothelioma: a single institution experience and long term follow up.
    Malekzadeh P; Good M; Hughes MS
    Int J Hyperthermia; 2021; 38(1):326-331. PubMed ID: 34139940
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for patients with peritoneal carcinomatosis from colorectal cancer: a phase II study from a Chinese center.
    Huang CQ; Yang XJ; Yu Y; Wu HT; Liu Y; Yonemura Y; Li Y
    PLoS One; 2014; 9(9):e108509. PubMed ID: 25259574
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial.
    de Boer NL; van Kooten JP; Burger JWA; Verhoef C; Aerts JGJV; Madsen EVE
    BMJ Open; 2019 May; 9(5):e026779. PubMed ID: 31092657
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal mesothelioma: preliminary results and survival analysis.
    Hubert J; Thiboutot E; Dubé P; Cloutier AS; Drolet P; Sideris L
    Surg Oncol; 2015 Mar; 24(1):41-6. PubMed ID: 25680983
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for limited peritoneal metastasis. The PSOGI international collaborative registry.
    Arjona-Sanchez A; Aziz O; Passot G; Salti G; Esquivel J; Van der Speeten K; Piso P; Nedelcut DS; Sommariva A; Yonemura Y; Turaga K; Selvasekar CR; Rodriguez-Ortiz L; Sanchez-Hidalgo JM; Casado-Adam A; Rufian-Peña S; Briceño J; Glehen O
    Eur J Surg Oncol; 2021 Jun; 47(6):1420-1426. PubMed ID: 33298341
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis.
    Helm JH; Miura JT; Glenn JA; Marcus RK; Larrieux G; Jayakrishnan TT; Donahue AE; Gamblin TC; Turaga KK; Johnston FM
    Ann Surg Oncol; 2015 May; 22(5):1686-93. PubMed ID: 25124472
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Baratti D; Kusamura S; Cabras AD; Dileo P; Laterza B; Deraco M
    Ann Surg Oncol; 2009 Feb; 16(2):463-72. PubMed ID: 19082859
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Justified for Biphasic Variants of Peritoneal Mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International Registry.
    Votanopoulos KI; Sugarbaker P; Deraco M; Morris D; Glehen O; Elias D; De Simone M; Robella M; Heyd B; Kusamura S; Baratti D; Chouliaras K; Russell G; Shen P; Levine EA;
    Ann Surg Oncol; 2018 Mar; 25(3):667-673. PubMed ID: 29260418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unusually favorable outcome of 6 consecutive patients with diffuse malignant peritoneal mesothelioma treated with repeated doses of intraperitoneal paclitaxel. A case series.
    Sugarbaker PH; Stuart OA
    Surg Oncol; 2020 Jun; 33():96-99. PubMed ID: 32561104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.